Zussa C, Polesel E, Rocco F, Galloni M, Frater R W, Valfrè C
Department of Cardiac Surgery, Treviso Regional Hospital, Italy.
J Card Surg. 1991 Dec;6(4):432-8. doi: 10.1111/j.1540-8191.1991.tb00342.x.
Failure of reconstructive procedures of the mitral valve is often ascribed to diffuse alteration of the subvalvular apparatus, which prevents the utilization of well-established techniques such as chordal transposition or shortening. For this reason, in 1986 after 2 years of animal experiments, we started the clinical use of expanded-polytetrafluoroethylene mitral chordae. Details of the surgical procedure are presented. Our experience is based on 51 patients with a mean follow-up of about 20 months (range 3-57). Four patients had the valve replaced during the same operation: one patient died later of cardiac failure and two underwent reoperation, 8 and 18 months after operation. Forty-one patients are in New York Heart Association Functional Class I and three in Class II. We suggest this technique in association with other traditional procedures to increase the number of mitral valves repaired, mostly because of degenerative etiology.
二尖瓣重建手术的失败常常归因于瓣下结构的弥漫性改变,这使得诸如腱索移位或缩短等成熟技术无法应用。因此,在经过2年的动物实验后,我们于1986年开始在临床中使用膨体聚四氟乙烯二尖瓣腱索。文中介绍了手术步骤的详细情况。我们的经验来自51例患者,平均随访时间约为20个月(范围3 - 57个月)。4例患者在同一次手术中进行了瓣膜置换:1例患者术后死于心力衰竭,2例患者在术后8个月和18个月接受了再次手术。41例患者心功能为纽约心脏协会功能分级I级,3例为II级。我们建议将该技术与其他传统手术相结合,以增加二尖瓣修复的数量,主要是因为病因多为退行性病变。